Krystal A Irizarry1, Diana R Mager2, Lucila Triador3, Michael J Muehlbauer4, Andrea M Haqq3, Michael Freemark1,4. 1. Division of Pediatric Endocrinology and Diabetes, Duke University Medical Center, Durham, North Carolina. 2. Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada. 3. Division of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada. 4. Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Abstract
OBJECTIVE: Macronutrient regulation of hyperphagia and adiposity in Prader-Willi syndrome (PWS) is poorly understood. We compared fasting and postprandial concentrations of hormones and metabolites in eight PWS children (age 9-18 years) fed, in random order, low carbohydrate, high-fat (LC, 15% carb; 65% fat; 20% protein) and low-fat, high carbohydrate (LF, 65% carb, 15% fat, 20% protein) diets matched for calories and protein. METHODS: Participants were randomized to consume either the LC or LF diet during a first hospital admission and the second diet during a subsequent admission. Blood samples were obtained after overnight fasting and 1 hour after a mixed meal. RESULTS: Relative to subjects consuming the LF diet, subjects consuming the LC diet had: lower postprandial insulin concentrations (P = 0.02); higher fasting GLP-1 AND GIP concentrations and increased postprandial GLP-1 (P < 0.02); reduced ratio of fasting ghrelin to GLP-1 (P = 0.0078); increased FFA and fatty acid oxidation, as assessed by concentrations of even-chain acylcarnitines (P < 0.001); lower fasting TG and TG/HDL ratio (P < 0.01); and higher concentrations of branch chain amino acids (P < 0.01). There were no changes in glucose, PYY, or adiponectin. CRP, AST and ALT were all higher (P < 0.01) on the LC diet. CONCLUSIONS: Increases in GLP-1 with low carbohydrate feeding and reductions in the ratio of ghrelin to GLP-1 might limit food intake and improve glycaemic control in PWS. Other potential benefits of carbohydrate restriction may include fat mobilization and oxidation and reductions in the TG/HDL ratio, a marker of insulin resistance. However, increases in CRP, AST and ALT necessitate longer-term studies of low carbohydrate efficacy and safety.
RCT Entities:
OBJECTIVE: Macronutrient regulation of hyperphagia and adiposity in Prader-Willi syndrome (PWS) is poorly understood. We compared fasting and postprandial concentrations of hormones and metabolites in eight PWSchildren (age 9-18 years) fed, in random order, low carbohydrate, high-fat (LC, 15% carb; 65% fat; 20% protein) and low-fat, high carbohydrate (LF, 65% carb, 15% fat, 20% protein) diets matched for calories and protein. METHODS:Participants were randomized to consume either the LC or LF diet during a first hospital admission and the second diet during a subsequent admission. Blood samples were obtained after overnight fasting and 1 hour after a mixed meal. RESULTS: Relative to subjects consuming the LF diet, subjects consuming the LC diet had: lower postprandial insulin concentrations (P = 0.02); higher fasting GLP-1 AND GIP concentrations and increased postprandial GLP-1 (P < 0.02); reduced ratio of fasting ghrelin to GLP-1 (P = 0.0078); increased FFA and fatty acid oxidation, as assessed by concentrations of even-chain acylcarnitines (P < 0.001); lower fasting TG and TG/HDL ratio (P < 0.01); and higher concentrations of branch chain amino acids (P < 0.01). There were no changes in glucose, PYY, or adiponectin. CRP, AST and ALT were all higher (P < 0.01) on the LC diet. CONCLUSIONS: Increases in GLP-1 with low carbohydrate feeding and reductions in the ratio of ghrelin to GLP-1 might limit food intake and improve glycaemic control in PWS. Other potential benefits of carbohydrate restriction may include fat mobilization and oxidation and reductions in the TG/HDL ratio, a marker of insulin resistance. However, increases in CRP, AST and ALT necessitate longer-term studies of low carbohydrate efficacy and safety.
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Daniela A Rubin; Susan J Clark; Jason Ng; Diobel M Castner; Andrea M Haqq; Daniel A Judelson Journal: Metabolism Date: 2014-12-02 Impact factor: 8.694
Authors: Ola Lindgren; Richard D Carr; Carolyn F Deacon; Jens J Holst; Giovanni Pacini; Andrea Mari; Bo Ahrén Journal: J Clin Endocrinol Metab Date: 2011-05-18 Impact factor: 5.958
Authors: Andrea M Haqq; Lillian F Lien; Jarol Boan; Michelle Arlotto; Cris A Slentz; Michael J Muehlbauer; James Rochon; Dianne Gallup; Ross L McMahon; James R Bain; Robert Stevens; David Millington; Mark D Butler; Christopher B Newgard; Laura P Svetkey Journal: Contemp Clin Trials Date: 2005-10-18 Impact factor: 2.226
Authors: Gary Frost; Michelle L Sleeth; Meliz Sahuri-Arisoylu; Blanca Lizarbe; Sebastian Cerdan; Leigh Brody; Jelena Anastasovska; Samar Ghourab; Mohammed Hankir; Shuai Zhang; David Carling; Jonathan R Swann; Glenn Gibson; Alexander Viardot; Douglas Morrison; E Louise Thomas; Jimmy D Bell Journal: Nat Commun Date: 2014-04-29 Impact factor: 14.919
Authors: G Muscogiuri; L Barrea; F Faggiano; M I Maiorino; M Parrillo; G Pugliese; R M Ruggeri; E Scarano; S Savastano; A Colao Journal: J Endocrinol Invest Date: 2021-04-23 Impact factor: 4.256